Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma

Leukemia and Lymphoma

Volumn 49, Issue 3, 2008, Pages 447-450

  Coleman, Morton ^a   Martin, Peter ^a   Ruan, Jia ^a   Furman, Richard ^a   Niesvizky, Ruben ^a   Elstrom, Rebecca ^a   George, Patricia ^a   Leonard, John ^a   Kaufmann, Thomas ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Chemotherapy; Low dose; Mantle cell lymphoma; Metronomic

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; ONDANSETRON; PREDNISONE; PROCARBAZINE;

ADULT; ANEMIA; ARTICLE; BEDTIME DOSAGE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; EVENING DOSAGE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; HUMAN; INFECTION; LEUKOCYTE COUNT; LOW DRUG DOSE; MANTLE CELL LYMPHOMA; MEDICAL RECORD REVIEW; MORNING DOSAGE; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; ETOPOSIDE; HUMANS; LEUKOCYTE COUNT; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; PREDNISONE; PROCARBAZINE; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 39749118652     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701837330     Document Type: Article

References (22)

1. Leonard, J. P., Schattner, E. J. and Coleman, M. (2001) Biology and management of mantle cell lymphoma. Curr Opin Oncol, 13, pp. 342-347.
2. Argatoff, L. H., Connors, J. M., Klasa, R. J., Horsman, D. E. and Gascoyne, R. D. (1997) Mantle cell lymphoma: A clinicopathologic study of 80 cases. Blood, 89, pp. 2067-2078.
3. Fisher, R. I., Dahlberg, S., Nathwani, B. N., Banks, P. M., Miller, T. P. and Grogan, T. M. (1995) A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood, 85, pp. 1075-1082.
4. Teodorovic, I., Pittaluga, S., Kluin-Nelemans, J. C., Meerwaldt, J. H., Hagenbeek, A. and van Glabbeke, M. (1995) Efficacy of four different regimens in 64 mantle-cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol, 13, pp. 2819-2826.
5. Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U. and Metzner, B. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German low grade lymphoma study group (GLSG). J Clin Oncol, 23, pp. 1984-1992.
6. Romaguera, J. E., Fayad, L., Rodriguez, M. A., Broglio, K. R., Hagemeister, F. B. and Frederick, B. (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol, 23, pp. 7013-7023.
7. Dreyling, M., Lenz, G., Hoster, E., Van Hoof, A., Gisselbrecht, C. and Schmits, R. (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood, 105, pp. 2677-2684.
8. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol, 17, p. 1244.
9. Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Hanel, A. and Metzner, B. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German low-grade lymphoma study group. Blood, 104, pp. 3064-3071.
10. Goy, A., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J. and Boral, A. (2006) Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study. J Clin Oncol, 24, p. 7512.
11. Hollister, D., Silver, R. T., Gordon, B. and Coleman, M. (1982) Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma. Cancer, 50, pp. 1690-1694.
12. Coleman, M., Boyd, D. B. and Bernhardt, B. (1986) COPBLAM: Infusion chemotherapy for large cell lymphoma. Clinical Applications of Continuous Infusion Chemotherapy and Concomitant Radiation Therapy, pp. 79-86. Plenum, New York, NY
13. George, P. and Coleman, M. (1993) The C3 regimen for resistant lymphoma: daily oral etoposide, chlorambucil, procarbazine, and prednisone. ASCO Meet Abstr, 12, p. 379.
14. Boyd, D. B., Coleman, M. and Papish, S. D. (1988) COPBLAM III: infusional combination chemotherapy for diffuse large cell lymphoma. J Clin Oncol, 6, pp. 425-433.
15. Coleman, M., Ruan, J., Furman, R. R., Niesvizky, R., Martin, P. and Leonard, J. P. (2007) Oral combination chemotherapy for refractory/ relapsed lymphoma with the PEP-C (C3) regimen (daily prednisone, etoposide, procarbazine, cyclophosphamide): Low-dose continuous metronomic multidrug therapy. ASCO Meet Abstr, 25, p. 8064.
16. Shaked, Y., Emmenegger, U. and Francia, G. (2005) Low dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res, 65, pp. 7045-7051.
17. Emmenegger, U., Man, S. and Shaked, Y. (2004) A comparative analysis of low dose metronomic cyclophosphamide reveals absent or low grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimen. Cancer Res, 64, pp. 3994-4000.
18. Man, S., Bocce, G. and Francia, G. (2002) Antitumor effects in mice of low dose (metronomic) cyclophosphamide administered through the drinking water. Cancer Res, 62, pp. 2731-2735.
19. Kerbel, R. S., Klement, G., Pritchard, K. I. and Kamen, B. (2002) Continuous low dose anti-angiogenesis/metronomic chemotherapy: From the research laboratory into the oncology clinic. Ann Oncol, 13, pp. 12-15.
20. Buchstein, R., Kerbel, R. S. and Shaked, Y. (2006) High dose celecoxib and metronomic "low dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res, 12, pp. 5190-5198.
21. Emmenger, U., Morton, G. C. and Francia, G. (2006) Low dose metronomic daily cyclophosphamide and weekly tirapazamine: A well tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res, 66, pp. 1664-1674.
22. Shaked, Y., Emmengger, U. and Man, S. (2005) Optimal biologic dose of metronomic chemotherapy regimen is associated with maximum antiangiogenic activity. Blood, 106, pp. 3058-3061.